Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IVX-A12 vs Arexvy in Older Adults
NCT06481579Phase 2Completed
- Sponsor
- Icosavax, Inc.
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of IVX-A12 in respiratory syncytial virus infection (RSV), human metapneumovirus infection (HMPV), sponsored by Icosavax, Inc.. Started Jun 2024; status: completed.
02
Drugs
IVX-A12
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT06481579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481579.